APELLIS PHARMACEUTICALS, INC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 706
- Market Cap
- $4.8B
- Website
- http://www.apellis.com
Clinical Trials
68
Active:37
Completed:17
Trial Phases
4 Phases
Phase 1:37
Phase 2:10
Phase 3:11
+1 more phases
Drug Approvals
2
FDA:2
Clinical Trials
Distribution across different clinical trial phases (61 trials with phase data)• Click on a phase to view related trials
Phase 1
37 (60.7%)Phase 3
11 (18.0%)Phase 2
10 (16.4%)Not Applicable
3 (4.9%)A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Not Applicable
Recruiting
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- Drug: APL-3007, pegcetacoplan (APL-2)Other: Placebo, Syfovre
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT07215390
- Locations
- 🇺🇸
Bay Area Retina Associates - Walnut Creek, Walnut Creek, California, United States
🇺🇸Cumberland Valley Retina Consultants (CVRC), Hagerstown, Maryland, United States
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
Not Applicable
Not yet recruiting
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- Drug: APL-2, Pegcetacoplan
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT07214740
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT07213960
- Locations
- 🇺🇸
Investigator Site 1, Chicago, Illinois, United States
🇺🇸Investigator Site 2, New York, New York, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Phase 3
Not yet recruiting
- Conditions
- Delayed Graft FunctionDeceased Donor Kidney TransplantEnd Stage Renal Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT07020832
Geographic Atrophy Long-Terms Outcomes Study
Completed
- Conditions
- Geographic Atrophy
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Apellis Pharmaceuticals, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT06499571
- Locations
- 🇦🇺
Sydney West Retina, Westmead, New South Wales, Australia
🇫🇷Centre Hospitalier de la Croix Rousse, Lyon Cedex 04, Rhone, France
🇩🇪Universitaetsklinikum Muenster, Münster, Nordrhein Westfalen, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found